AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced today the successful completion of an optimization project for Merck & Co., Inc. as part of an agreement for the delivery of candidate antibodies for therapeutic use.
“We look forward to continued success in this relationship with Merck.”
"One of the many applications of AnaptysBio's SHM-XEL™ platform is to optimize the binding properties of existing antibodies to meet challenging therapeutic design goals," said Tom Smart, chairman and chief executive officer for AnaptysBio. "We look forward to continued success in this relationship with Merck."
Under the terms of the agreement, Merck has worldwide rights to the development and commercialization of the candidate antibodies that were optimized by AnaptysBio using the SHM-XEL™ platform. In return, AnaptysBio has received an upfront payment and a success milestone payment for the delivery of optimized antibodies that met the agreed upon design criteria. In addition, AnaptysBio is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the delivered antibodies.
New molecule shows promise in protecting mice from influenza